Switchpoint Bio, a company pioneering scalable epigenomic profiling of the immune system, has entered into a partnership with the Fingenious® Ecosystem. The collaboration opens an opportunity to add deep immune biology to research on nationwide Finnish biobank samples, with the aim of improving the diagnosis, monitoring and treatment of diseases. With a single request and a single contract, Fingenious® gives access to all Finnish public biobanks, which together hold more than 14 million samples.